Generics· July 2, 2026 · 18 min read
Why Generic Jardiance Has Not Launched: Empagliflozin Patent Cliff
By Ran Chen#Generic Entry#Orange Book#SGLT2 Inhibitor
Topic
PBM
Pharmacy benefit managers, formulary exclusions, rebate strategy, specialty pharmacy routing, and payer contracting signals.
Generics· June 26, 2026 · 21 min read
Generic Tecfidera: Dimethyl Fumarate Patent Settlements and NADAC Erosion
By Ran Chen#Generics#Orange Book#PBM
Generics· June 25, 2026 · 19 min read
Generic Forteo: Drug-Device Pathways and PBM Exclusions
By Ran Chen#Generics#Orange Book#505(b)(2)
Generics· June 25, 2026 · 19 min read
Generic Gilenya: Dosing Patent Expiry and 99% Price Erosion
By Ran Chen#Generics#Orange Book#PBM
Generics· June 24, 2026 · 17 min read
Generic Entresto Market Entry: 95% Price Erosion and the Payer Formulary Transition
By Ran Chen#Generics#Generic Entry#Drug Pricing
Pricing & Access· June 6, 2026 · 9 min read
CVS Caremark GLP-1 coverage and formulary changes for 2026
By Ran Chen#GLP-1#CVS Caremark#PBM
Specialty· June 6, 2026 · 15 min read
GLP-1 specialty pharmacy mandatory routing: when your pharmacy can't fill the prescription
By Ran Chen#GLP-1#Specialty Pharmacy#Pharmacy Benefit
Pricing & Access· June 6, 2026 · 10 min read
OptumRx GLP-1 coverage: formulary tiers, PA criteria, and 2026 UM rules
By Ran Chen#GLP-1#OptumRx#Prior Authorization
Pricing & Access· June 3, 2026 · 15 min read
GLP-1 insurance coverage 2026: major payer guide
By Ran Chen#GLP-1#Payer Coverage#Prior Authorization